Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States

References

• National Cancer Institute. Adult non-Hodgkin lymphoma treatment (PDQ)–health professional version. [cited 2022 Dec 6]. Available from: https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq.
   Google Scholar
• Freedman A, Jacobsen E. Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol. 2020;95(3):316–327. doi: 10.1002/ajh.25696.
   PubMed Web of Science ®Google Scholar
• Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national LymphoCare study. J Clin Oncol. 2015;33(23):2516–2522. doi: 10.1200/JCO.2014.59.7534.
   PubMed Web of Science ®Google Scholar
• Monga N, Nastoupil L, Garside J, et al. Burden of illness of follicular lymphoma and marginal zone lymphoma. Ann Hematol. 2019;98(1):175–183. doi: 10.1007/s00277-018-3501-8.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA grants accelerated approval to mosunetuzumab-axgb for relapsed or refractory follicular lymphoma. [cited 2022 Dec 22]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-mosunetuzumab-axgb-relapsed-or-refractory-follicular-lymphoma
   Google Scholar
• Genentech, Inc. LUNSUMIO (mosunetuzumab-axgb): highlights of prescribing information. [cited 2023 Jan 3]. Available from: https://www.gene.com/download/pdf/lunsumio_prescribing.pdf
   Google Scholar
• Budde LE, Sehn LH, Matasar M, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23(8):1055–1065. doi: 10.1016/S1470-2045(22)00335-7.
   PubMed Web of Science ®Google Scholar
• Smare C, Lakhdari K, Doan J, et al. Evaluating partitioned survival and Markov decision-analytic modeling approaches for use in cost-effectiveness analysis: estimating and comparing survival outcomes. Pharmacoeconomics. 2020;38(1):97–108. doi: 10.1007/s40273-019-00845-x.
   PubMed Web of Science ®Google Scholar
• Guzauskas GF, Masaquel A, Reyes C, et al. Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US. J Med Econ. 2018;21(10):960–967. doi: 10.1080/13696998.2018.1489254.
   PubMed Web of Science ®Google Scholar
• Choe JH, Abdel-Azim H, Padula WV, et al. Cost-effectiveness of axicabtagene ciloleucel and tisagenlecleucel as second-line or later therapy in relapsed or refractory diffuse large B-cell lymphoma. JAMA Netw Open. 2022;5(12):e2245956. doi: 10.1001/jamanetworkopen.2022.45956.
   PubMed Web of Science ®Google Scholar
• Perales MA, Kuruvilla J, Snider JT, et al. The cost-effectiveness of axicabtagene ciloleucel as second-line therapy in patients with large B-cell lymphoma in the United States: an economic evaluation of the ZUMA-7 trial. Transplant Cell Ther. 2022;28(11):750.e1-750–e6. doi: 10.1016/j.jtct.2022.08.010.
   Google Scholar
• Matasar M, Masaquel A, R SH, et al. US cost-effectiveness analysis of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. J Med Econ. 2023;26(1):1134–1144. doi: 10.1080/13696998.2023.2254640.
   PubMed Web of Science ®Google Scholar
• Oluwole OO, Ray MD, Zur R, et al. Cost-effectiveness of axicabtagene ciloleucel versus mosunetuzumab in relapsed/refractory follicular lymphoma in the US. Blood. 2023;142(Supplement 1):5082–5082. doi: 10.1182/blood-2023-186548.
   Google Scholar
• Oluwole OO, Patel AR, Vadgama S, et al. An updated cost-effectiveness analysis of axicabtagene ciloleucel in second-line large B-cell lymphoma patients in the United States. J Med Econ. 2024;27(1):77–83. doi: 10.1080/13696998.2023.2290832.
   PubMed Web of Science ®Google Scholar
• Oluwole OO, Ray MD, Rosettie KL, et al. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory follicular lymphoma in the United States. Value Health. 2024;S1098-3015(24):02334-9. doi: 10.1016/j.jval.2024.04.003.
   PubMed Web of Science ®Google Scholar
• Arias E, Xu J, Tejada-Vera B, et al. United States life tables, 2020. Natl Vital Stat Rep. 2022;71(2):1–18.
   Google Scholar
• Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–1103. doi: 10.1001/jama.2016.12195.
   PubMed Web of Science ®Google Scholar
• Potnis KC, Di M, Isufi I, et al. Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma. Blood Adv. 2023;7(5):801–810. doi: 10.1182/bloodadvances.2022008097.
   PubMed Web of Science ®Google Scholar
• Lin M, Weiss J, Phillips TJ, et al. Cost effectiveness of mosunetuzumab and CAR-T cell therapy in relapsed/refractory follicular lymphoma. Blood. 2023;142(Supplement 1):256–256. doi: 10.1182/blood-2023-182244.
   Google Scholar
• Kambhampati S, Saumoy M, Schneider Y, et al. Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma. Blood. 2022;140(19):2024–2036. doi: 10.1182/blood.2022016747.
   PubMed Web of Science ®Google Scholar
• Vijenthira A, Kuruvilla J, Crump M, et al. Cost-Effectiveness analysis of frontline polatuzumab-rituximab, cyclophosphamide, doxorubicin, and prednisone and/or second-line chimeric antigen receptor T-cell therapy versus standard of care for treatment of patients with intermediate- to high-risk diffuse large B-cell lymphoma. J Clin Oncol. 2023;41(8):1577–1589. doi: 10.1200/JCO.22.00478.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3–9. doi: 10.1016/j.jval.2021.11.1351.
   PubMed Web of Science ®Google Scholar
• Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas V.2.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. [cited 2022 Mar 21]. To view the most recent and complete version of the guideline, go online to NCCN.org.
   Google Scholar
• McGough SF, Shamas N, Wang J, et al. An external control for mosunetuzumab using real-world data in follicular lymphoma in the third or subsequent lines of systemic therapy. Blood. 2022;140(Supplement 1):3658–3660. doi: 10.1182/blood-2022-159640.
   Google Scholar
• Bosch F, Kuruvilla J, Vassilakopoulos TP, et al. Indirect treatment comparisons of mosunetuzumab with third- and later-line treatments for relapsed/refractory follicular lymphoma. Clin Lymph Myel Leuk. 2024;24(2):105–121. doi: 10.1016/j.clml.2023.09.007.
   PubMed Web of Science ®Google Scholar
• Buchanan AL, Hudgens MG, Cole SR, et al. Generalizing evidence from randomized trials using inverse probability of sampling weights. J R Stat Soc Ser A Stat Soc. 2018;181(4):1193–1209. doi: 10.1111/rssa.12357.
   PubMed Web of Science ®Google Scholar
• Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940–947. doi: 10.1016/j.jval.2012.05.004.
   PubMed Web of Science ®Google Scholar
• Latimer N. NICE DSU technical support document 14: undertaking survival analysis for economic evaluations alongside clinical trials – extrapolation with patient-level data. Report by the decision support unit. Sheffield, UK: School of Health and Related Research; 2011 (last updated March 2013).
   Google Scholar
• AnalySource®. Reprinted with permission by First Databank, Inc. All rights reserved; © 2023 [cited 2023 Mar 10]. Available from: https://www.analysource.com/
   Google Scholar
• Centers for Medicare & Medicaid Services. Physician fee schedule; 2022. Available from: https://www.cms.gov/medicare/physician-fee-schedule/search/overview.
   Google Scholar
• Lin S-W, Shapouri S, Parisé H, et al. Budget impact of introducing fixed treatment duration mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the USA. Pharmacoeconomics. 2024;42(5):569–582. doi: 10.1007/s40273-024-01358-y.
   Google Scholar
• Centers for Medicare & Medicaid Services. Clinical diagnostic laboratory fee schedule; 2022. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/Clinical-Laboratory-Fee-Schedule-Files.
   Google Scholar
• Betts KA, Thuresson PO, Felizzi F, et al. US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma. J Comp Eff Res. 2020;9(14):1003–1015. doi: 10.2217/cer-2020-0057.
   PubMed Web of Science ®Google Scholar
• Kite Pharma Inc. YESCARTA: highlights of prescribing information. [cited 2022 Apr 18]. Available from: https://www.fda.gov/media/108377/download.
   Google Scholar
• Novartis Pharmaceuticals Corporation. KYMRIAH (tisagenlecleucel): highlights of prescribing information. [cited 2022 Jun 1]. Available from: https://www.fda.gov/media/107296/download.
   Google Scholar
• Zinzani PL, Flinn IW, Yuen SLS, et al. Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma. Blood. 2020;136(23):2628–2637. doi: 10.1182/blood.2020005588.
   PubMed Web of Science ®Google Scholar
• Genentech, Inc. GAZYVA (obinutuzumab): highlights of prescribing information. [cited 2022 Apr 18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125486s029lbl.pdf.
   Google Scholar
• Pickard AS, Law EH, Jiang R, et al. United States valuation of EQ-5D-5L health states using an international protocol. Value Health. 2019;22(8):931–941. doi: 10.1016/j.jval.2019.02.009.
   PubMed Web of Science ®Google Scholar
• Wild D, Walker M, Pettengell R, et al. PCN62 utility elicitation in patients with follicular lymphoma. Value in Health. 2006;9(6):A294. doi: 10.1016/S1098-3015(10)63491-2.
   Web of Science ®Google Scholar
• Cognet M, Taieb V, Bec M, et al. Utility values for patients with indolent non-Hodgkin lymphoma (INHL) in top five European countries (EU-5). Haematologica. 2015;1:578.
   Google Scholar
• United States Bureau of Labor Statistics. Consumer price index for all urban consumers: medical care (CUSR0000SAM); 2022 [cited 2022 Dec 5]. Available from: https://www.bls.gov/data/.
   Google Scholar
• Genentech, Inc. RITUXAN (rituximab) injection: highlights of prescribing information. [cited 2022 Apr 18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf
   Google Scholar
• Teva Pharmaceuticals USA Inc. BENDEKA: highlights of prescribing information. [cited 2022 Apr 18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208194s024lbl.pdf
   Google Scholar
• Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Management of Immunotherapy-Related Toxicities V.1.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. [cited 2022 May 3]. To view the most recent and complete version of the guideline, go online to NCCN.org.
   Google Scholar
• Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas V.1.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. [cited 2024 Jan 23]. To view the most recent and complete version of the guideline, go online to NCCN.org.
   Google Scholar
• Monga N, Garside J, Gurung B, et al. Cost-Effectiveness analyses, costs and resource use, and health-related quality of life in patients with follicular or marginal zone lymphoma: systematic reviews. Pharmacoecon Open. 2020;4(4):575–591. doi: 10.1007/s41669-020-00204-z.
   PubMed Web of Science ®Google Scholar
• Thompson S, van Agthoven M. Cost-Effectiveness of 90Y-ibritumomab tiuxetan (90Y-Zevalin) versus rituximab monotherapy in patients with relapsed follicular lymphoma. Blood. 2005;106(11):2436–2436. doi: 10.1182/blood.V106.11.2436.2436.
   PubMed Web of Science ®Google Scholar
• Chong EA, Ruella M, Schuster SJ, Lymphoma Program Investigators at the University of Pennsylvania. Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy. N Engl J Med. 2021;384(7):673–674. doi: 10.1056/NEJMc2030164.
   PubMed Web of Science ®Google Scholar
• National institute for Health and Care Excellence. Final draft guidance: glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments [TA927]. 17 October 2023 ed. London, UK: national institute for Health and Care Excellence; 2023.
   Google Scholar
• Leonard JP, Trneny M, Izutsu K, et al. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019;37(14):1188–1199. doi: 10.1200/JCO.19.00010.
   PubMed Web of Science ®Google Scholar
• Milrod C, Kim KW, Ollila T, et al. Correlation between PFS and OS in FL: implications for clinical trial endpoint selection. Blood. 2023;142(Supplement 1):4395–4395. doi: 10.1182/blood-2023-177626.
   Google Scholar